Sen. Sanders urges Novo Nordisk to reduce prices of Ozempic and Wegovy, stating lower costs are necessary for accessibility and financial sustainability for consumers and governments.
Senate Committee requests internal communications on the pricing disparity of these drugs in the US compared to other countries and questions why similar compounds in Ozempic and Wegovy have different price points.
Novo Nordisk agrees on the importance of access to treatments but emphasizes the complexity of understanding diseases, drug development, and healthcare systems, committing to collaboration for affordability.
Sanders plans to also examine Eli Lilly for their rival medications' prices, pointing out this issue extends beyond Novo Nordisk, highlighting a broader concern within the industry.
[
add
]
[
|
|
...
]